ioural disturbances interfering with daily living. The clinical diagnosis of dementia is based upon criteria referring to the inadequacy of being in charge of oneself [1, 2] . Consequently, the actual cases of dementia are discovered late in the disease process. The clinical diagnostic accuracy for full-blown dementia has improved over the years leaning on these well-established criteria. However, the differential diagnostics of the disorders probably proceeding to dementia later on is still problematic. Adequate dementia treatment and care require knowledge about specific neurodegenerative processes in order to diagnose the actual cause of the dementia disorder. This depends on the physician's individual capacity to integrate such evidence with clinical skills based on their own clinical experience. As Alzheimer's dementia (AD) is found to be the far most frequent type of dementia [3] , substantial efforts have been made to establish clinical criteria for the stages that precede dementia, i.e. mild cognitive impairment (MCI) [4] [5] [6] . However, there is still no universal agreement upon which criteria to use to be able to foresee the development of MCI to AD. We therefore welcome the initiative taken by Dubois et al. [7] to propose a new framework of diagnostic criteria for AD aiming to diagnose prodromal AD. The core principle of these criteria [7] is based upon the presence of consistent episodic memory disturbance that together with objective biomarker pathology as supportive diagnostic features recognize AD preceding the dementia syndrome. Among the currently available biomarkers for AD, there is evidence for the existence of medial temporal lobe atrophy (MTA) measured by magnetic resonance imaging (MRI) scans, altered cerebral blood flow (CBF) measured by nuclear imaging [single-photon emission computer tomography (SPECT)/positron emission tomography] and pathological alterations in the ratios of the proteins ␤ -amyloid (A ␤ 42), phosphorylated tau (P-tau) and total tau (T-tau) in the cerebrospinal fluid (CSF) in patients developing AD [8] [9] [10] . Based on this knowledge, Dubois et al. [7] proposed their new set of criteria aiming at identifying pre-dementia AD before it progresses to dementia.
Aims
As patient material for clinical trials is based upon a substantial flow of a selection of patients with a high a priori incidence of the target disease, the proposed new criteria [7] need to be validated in clinical settings. Our aim was to validate the proposed new criteria [7] in a naturalistic sample of patients with memory disturbances. We were also interested in comparing the concordance in diagnosing AD using a broad clinical approach with access to all possible biomarkers including those proposed by Dubois et al. [7] with clinical evaluation without access to such, using the definitions of the traditional disease classification systems DSM-IV and ICD-10.
Materials and Methods

Settings
The Karolinska Memory Clinic, Huddinge, recruits approximately 450 new patients each year. Most referrals are from GPs, but there are also those referred for second opinion from other clinics. Based at the department of geriatric medicine at Karolinska University Hospital, Huddinge, the memory clinic has the responsibility for all out-patients with memory problems and possibly dementia disorders under the age of 65 in the Stockholm catchment area. Additionally, the clinic is in charge of dementia disorders in the geriatric population in the adjacent hospital area. The population is therefore highly heterogeneous with respect to family history of dementia, age, socioeconomic background, social and physical activities, level of education, medical history and level of daily functioning. The diagnostic work-up is made according to a clinical framework including a team of geriatricians, neurologists, neuropsychologists, nurses, occupational therapists, psychiatrists and speech therapists [11] . The diagnoses are set by a senior consultant in consensus with the team members involved in each case. The memory clinic has to a large extent involved neuroimaging as well as markers from plasma and serum, CSF and genetic material as possible diagnostic markers sensitive to change in dementia. These are used as a supplement to the clinical routine work-up. There is a large clinical trial unit running parallel to the clinical routine out-patient clinic that especially deals with the interpretation and involvement of these markers in the diagnostic procedure as well as in intervention trials.
Patient Characteristics
A total of 600 patient files ( fig. 1 ) with consecutive new referrals from 2001 to 2006 with a cerebral MRI and/or CT scan to exclude patients with intra-cerebral tumours, normal pressure hydrocephalus and cortical strokes were retrospectively investigated in order to obtain cases with (1) an objective history of episodic memory dysfunction and (2) CSF analyses, CBF or measurements of MTA. Based upon these criteria, 150 patients [66% women, mean Mini-Mental State Examination sum score (MMSE) [12] of 26 points (range = 18-30), mean age = 59 years (range = 41-78), mean Clinical Dementia Rating (CDR) [13] of 0.5] were included. As our sample was retrospectively drawn from the routine clinical records and did not represent a pre-selected research cohort, it was a true naturalistic sample where the clinical presentation of each patient set the agenda for added diagnostics. None of the patients had gone through all the procedures available in the dementia work-up. The frequency of the procedures used is shown in table 1 . In order to avoid diagnostic circularity, a rediagnostic procedure was made by 2 independent experienced geriatricians on the basis of all relevant accessible clinical information based on the clinical consensus report from each patient with access to the MMSE and CDR sum scores, but without any knowledge of the raw scorings of the episodic memory test results using the Ray Auditory Verbal Learning Test (RAVLT) [14] or the biomarkers in question. The patient's ApoE status was not available to the study physicians. The intra-rater reliability between the 2 study physicians was 0.69.
Assessments
As the core feature in the suggested new criteria by Dubois et al. [7] is persistent reduction in episodic memory function, we included patients who had been examined with the RAVLT [14] . This is a list of 15 words presented to the patient 5 times, reflecting episodic memory capacity (immediate and delayed recall). The cut-off for the pathological delayed recall test was set at ! 6 (of the total of 15 words) according to previous findings [15] . Global cognitive function was assessed by the MMSE [12] performed according to standard procedure by the routine clinical physicians seeing the patients at the first consultation at the memory clinic. Memory function including RAVLT was assessed by a trained neuropsychologist. A grading of the cognitive impairment using CDR [13] was made by a senior consultant when the patients were discussed in the diagnostic consensus meeting. The diagnosis was made according to the consensus criteria for MCI by Winblad et al. [5] , the ICD 10/DSM-IV criteria for dementia [1, 2] , the NINCDS-ADRDA for AD [16] , the NINCDS-AIREN for vascular dementia (VaD) [17] and the Manchester Criteria for Frontotemporal Dementia, (FLD) [18] . For the diagnosis of subjective cognitive impairment (SCI) we used the ICD-10 classification of 'Z03.3 = observation for possible neuro-organic disorder' [1] when the patient had subjective memory problems that could not be confirmed objectively. When the dementia diagnosis was unclear, the ICD-10 classification for unspecified dementia, dementia UNS, was used [1] .
MRI
A standardized protocol for geriatric purposes was used, performed on a 1.5 T Siemens Vision (Symfoni and Avanto) scanner (Siemens, Erlangen, Germany). Visual assessments were based on a T 1 -weighted 3D MP-RAGE (3-dimensional magnetization prepared rapid gradient echo) sequence, TR = 11.4 ms, TE = 4.4 ms and flip angle = 10. The coronal plane was chosen, perpendicular to a line between the anterior and posterior commissures in the midsagittal plane. This sequence yields 72 continuous coronal slices, with a slice thickness of 2.5 mm, covering the whole brain. A good separation between grey and white matter was obtained.
Visual Rating on MRI
MTA was assessed visually according to the Scheltens scale [8] . It is based on coronal 3D MP-RAGE, and the visual assessment is performed in the height of the middle of the brainstem after leaving the amygdala in front.
An MTA score was attributed by estimating the widths of the choroidal fissure, temporal horn of the lateral ventricle and the height of the hippocampus. The scores ranged from 0 (no atrophy) to 4 (severe atrophy), where grades 3 and 4 are referred to as pathological.
Left and right medial lobe atrophy was rated separately. The assessment was done by one rater (L.C.) and the intra-rater reliability was 0.72 on the right side and 0.74 on the left side. The mean MTA in this study was 1.01 on the right side and 1.1 on the left side.
Single-Photon Emission Computer Tomography
The cerebral metabolism reflected by CBF was examined with SPECT using a visual assessment combined with a semi-quantitative method (BRASS) described earlier [9] . SPECT perfusion was performed according to standard clinical procedure after in- RAVLT delayed recall = Rey Auditory Verbal Learning Test; MTA = rating of the medial temporal lobe atrophy on MRI scans; CBF = cerebral blood flow rated on SPECT (single-photon emission computer tomography) scans by the BRASS method; CSF = cerebro spinal fluid.
Lack of Accuracy for the Proposed 'Dubois Criteria' in Alzheimer's Disease Dement Geriatr Cogn Disord 2010;30:374-380 377 jection of 1,000 MBq Tc-99m-HMPAO in quiet surroundings with the patient's eyes closed. Acquisition was started 30 min after injection. Data were collected in 60 projections evenly spread through 360° with a triple-headed rotating gamma camera (Picker Irix, Ohio, USA) and a total acquisition time of 22 min. Tomographic slices were reconstructed using an iterative algorithm (Hosem, Nuclear Diagnostics AB, Stockholm, Sweden) with Chang attenuation correction (attenuation coefficient: 0.12/cm). Data were formatted as a 3D dataset with 128 ! 128 ! 64 voxels (64 transversal sections) and with a voxel size of 1.75 ! 1.75 ! 3.5 mm 3 . The reconstructed datasets were post-filtered with a Butterworth filter (cut-off 1.0/cm). The resolution in a tomographic slice was measured at 10.2 mm full width at half maximum.
CSF Analyses
CSF was obtained by standard procedure lumbar puncture in all patients accepting to undergo this task. All samples were stored at -80 ° C until analysis. CSF T-tau, A ␤ 42 and P-tau were determined using a sandwich ELISA constructed to measure these proteins [10] . Two internal CSF pools were run on each ELISA to assure its reproducibility [18] . The reference values (A ␤ 42 ! 427 ng/l, T-tau 1 445 ng/l or P-tau 1 74 ng/l) published by Wallin et al. [10] were used as cut-off values.
Statistical Procedures
The Spearman rank order correlation coefficient was used to measure the association between the diagnosis of MCI and the biomarkers. The concordance/agreement between the diagnosis of MCI and the biomarkers MRI, SPECT and RAVLT was performed with -and weighted statistics. For the analyses, the variables were divided into 3 categories in the following way: diagnoses (0 + 1 = normal + SCI, 2 = MCI and 3 = AD), MRI (0 + 1 = no atrophy, 2 = slight atrophy and 3 + 4 = extensive atrophy), SPECT (0 = no pathology, 1 = slight pathology and 2 = extensive pathology) and RAVLT delayed recall (3 + 4 = sum scores 15-8, 2 = sum score 7-4 and 1 = sum scores 3-0). Judgements of correlation coefficients and values were made according to Landis and Koch [19] 
Results
The distribution of the clinical diagnosis made by the two independent geriatricians according to the traditional classification systems was: SCI (n = 18), MCI (n = 78), AD (n = 23), VaD (n = 15), FLD (n = 3), dementia UNS (n = 10) and normal (n = 3). The concordance between the routine clinical staff who used the results of the biomarkers (MRI, SPECT scans and the CSF analyses) in the clinical work-up and the study physicians blinded to the biomarkers in question was 90% for the AD diagnosis and 66% for the total of the other diagnoses.
Our main focus was to investigate the applicability of the Dubois criteria [7] to identify possible prodromal AD cases in our clinically diagnosed SCI and MCI patients. A second aim was to validate the Dubois criteria [7] in patients with a clinically established AD syndrome according to the traditional diagnostic criteria.
For the statistical analyses, we therefore excluded the patients with all other clinical dementia diagnoses (VaD, FLD and dementia UNS, n = 28) and the 3 patients who were cognitively normal. Thus, 119 patients with SCI, MCI or AD were initially studied. Of these, only 110 patients had performed RAVLT. The majority had had a rating of the MTA and CBF done and in about 50% of these patients analyses of dementia biomarkers in CSF were performed ( table 1 ) .
Of the 18 patients with the clinical diagnosis of SCI, only 3 fulfilled the core criteria of Dubois (i.e. impaired episodic memory with a RAVLT ! 6; table 2 ). In table 3 , we show the distribution of pathological biomarkers versus the clinical diagnoses SCI, MCI and AD. Two of the SCI patients also fulfilled 1 additional Dubois criterion having pathological CSF ( table 3 ) . Thus, compared with the traditional criteria, the Dubois criteria could identify S CI = Subjective cognitive impairment; MCI = mild cognitive impairment; AD = Alzheimer's dementia.
2 prodromal AD patients among the SCI cases. Similarly, the Dubois criteria identified 5 prodromal AD patients among the 78 MCI patients; where 4 patients had all 3 additional features pathological and 1 patient had pathological CBF ( table 3 ) . Among the total number of clinically diagnosed SCI and MCI patients (n = 96), 26% (n = 25) fulfilled the core criteria of pathological episodic memory levels tested with RAVLT but no additional features according to the Dubois criteria. Thus, 6 1 additional features identified 7.3% (7/96) 'true' prodromal Alzheimer cases in the group of 96 clinically non-demented patients.
We also investigated whether the suggested criteria by Dubois et al. [7] do identify Alzheimer cases in a sample of 23 patients with a clinical diagnosis of AD according to the standard (ICD-10 or DSM-IV) criteria; 95.6% (22/23) patients had a pathological episodic memory, while 54.5% (12/22) of them had 6 1 additional features. Thus, 54.5% of the patients with an AD diagnosis according to the traditional diagnostic criteria also fulfilled the criteria of Dubois et al. [7] .
The analyses showed a poor to moderate concordance (weighted = 0.18-0.52) between the added procedures and biomarkers (RAVLT, MRI, SPECT and CSF) and the clinical diagnoses (SCI, MCI and AD). However, delayed recall, objectively assessed by RAVLT, was the most sensitive biomarker to detect AD cases (weighted = 0.52). On a group level, there were no significant correlations between any of the suggested procedures or biomarkers and the diagnosis of MCI.
Discussion
The proposed new research criteria for the diagnosis of AD are aiming to identify patients with an AD phenotype and probable AD before the patients have reached a stage where the symptoms interfere with daily living and the dementia syndrome is unpreventable [7] . The authors of the proposed new criteria, however, call for caution until further validation exists [20] .
The proposed new criteria [7] positively did identify 11% (2/18) and 6% (5/78) possible pre-AD cases in our clinically diagnosed patients with SCI and MCI phenotype, respectively. Thus, in our SCI and MCI sample, the Dubois criteria identified only a few patients with pre-AD showing that the traditional classification criteria, at least in our sample, still are useful. Our sample is a naturalistic patient sample from a memory clinic but is highly selective according to age as the clinic is appointed to investigate all patients with memory disturbances ! 65 years of age in the whole Stockholm region. Thus, our clinical sample is younger than in other memory clinic settings and the proportion of patients with SCI and MCI as compared with patients with dementia is high. The pre-test probability for being diagnosed as having AD is therefore lower compared to other clinical settings with older patient populations. Thus, the actual pre-AD cases in our sample may be truly low as the use of the Dubois criteria suggests here, although the conversion rate of MCI to AD in our clinic after 3 years of follow-up [11] is in concordance with international findings.
Interestingly, the Dubois criteria identified 12 cases of AD in our sample with 23 patients diagnosed as having a dementia syndrome due to AD according to the traditional classification systems. This discrepancy could be due to the difficulties of defining norms for biomarker pathology.
One problem with the proposed Dubois criteria is that there are no established cut-off levels for dementia biomarkers in CSF making the identification of possible pre-AD cases in clinical samples vary according to which cutoffs are used. Hansson et al. [21] proposed that MCI cases having a combination of A ␤ 42 ! 530 ng/l and T-tau 1 350 ng/l have a potential to convert to AD. Interestingly, an examination of our MCI patient sample using the cut-offs suggested by Hansson et al. [21] showed that only 1 patient in our material clinically diagnosed as having MCI met these cut-off values. The rates of conversion from MCI to AD vary according to age, neuropsychological profile and the definition of MCI [22, 23] . Our findings suggest that we still should focus on systematic The Dubois-criteria identified in total 7 patients in the SCI and MCI groups with prodromal AD. clinical follow-up of patients over several years with repetitive collection of both clinical and biological material to clinically detect conversion from MCI to AD to be able to conclusively validate the biomarkers in question.
Pooled data from the ICTUS study aiming to evaluate the multi-centre variability of the MTA measurements using the Scheltens' scale [8] including 117 mild to moderate AD patients pinpoints that there is a biological variability in MTA to be aware of when using MTA as a biomarker for inclusion and for outcome measures in clinical trials [24] . Our study shows that MTA was normal or questionably pathological in 82.6% of the clinically diagnosed AD patients. A possible interpretation is that our sample is younger with a low degree of global cognitive deficits and that it might be more relevant to measure the atrophy in more anterior areas than suggested by the Scheltens method [8] .
Furthermore, the DESCRIPA study, aiming to develop screening guidelines and clinical criteria for pre-dementia AD in a pooled sample of 881 patients from 20 European memory clinics, reveals that criteria requiring MRI scanning and CSF sampling will be difficult to apply as part of regular routine [25] . These findings urge us to also focus on the development of other valid possible biomarkers that are less time and economically demanding for clinical use in all settings.
Conclusion
We need to be able to push the diagnosis of AD prior to the development of ADL decline to be able to prevent the progression to dementia when disease-modifying treatment becomes available. To be able to do so, we need clinically relevant assessment tools that are accurate, trustworthy and clinician friendly in order to be useful in everyday clinical work. The detection of new biomarkers valid at an early stage of AD is highly warranted. Existing evidence is based on highly selected samples from memory clinic settings where there is a substantial risk of circularity and work-up bias. Thus, it is not unexpected that there is a considerable lack of accuracy of the proposed new research criteria for AD [7] in a heterogeneous sample of patients. Our findings might additionally be a brick in the large puzzle redefining the criteria for AD that currently might be regarded as a disease cluster with different phenotypes in early phases. We conclude that there still is a need to develop refined diagnostic criteria for dementia disorders which are reliable and applicable in early disease phases in clinical settings.
